Opioid Treatment Programs and Related Federal Regulations

The use of opioid medications to treat opioid addiction is subject to federal regulations beyond those that apply to the same medications used for other purposes (e.g., treating pain). The medications methadone and buprenorphine are both opioids; their use to treat opioid addiction is often called opioid substitution therapy, opioid replacement therapy, or opioid agonist treatment. Federally certified opioid treatment programs (OTPs)—often called methadone clinics—offer these opioid medications in addition to counseling and other services for individuals addicted to heroin or other opioids. With few exceptions, the use of methadone to treat opioid addiction is limited to OTPs; however, physicians who wish to treat opioid addiction using buprenorphine may obtain a waiver to do so outside an OTP. A non-opioid medication used in the treatment of opioid addiction, naltrexone, may be used by OTPs, physicians with waivers, or anyone with the authority to write prescriptions.

To understand how OTPs are regulated, it is helpful to have some background information about the medications used to treat opioid addiction and how each is regulated.

Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT) is the combined use of medication and other services to treat addiction. Three medications are currently used in MAT for opioid addiction: methadone, buprenorphine, and naltrexone (naloxone, a medication used to reverse opioid overdose, is not used to treat opioid use disorders).

Methadone
Methadone is a full opioid agonist, meaning it binds to and activates opioid receptors in the brain. Methadone carries risk of abuse but is less addictive than some other full opioid agonists (e.g., heroin). Methadone suppresses withdrawal symptoms in detoxification therapy and controls the craving for opioids in maintenance therapy.

Buprenorphine
Buprenorphine is a partial opioid agonist, meaning it binds to opioid receptors in the brain and activates them, but not as much as full opioid agonists. Buprenorphine carries risk of abuse but is less addictive than methadone. Like methadone, buprenorphine is used for detoxification and maintenance therapy.

Naltrexone
Naltrexone is an opioid antagonist, meaning it binds to opioid receptors but does not activate them; it prevents opioid agonists from binding to and activating opioid receptors. Naltrexone carries no known risk of abuse. Naltrexone is used for relapse prevention because an individual on naltrexone who uses opioids will not experience the effects of that opioid.

Regulatory Framework

Two overlapping systems of federal law apply to MAT for opioid addiction: one regulating pharmaceuticals and the other regulating controlled substances.

Federal Food, Drug, and Cosmetic Act (FFDCA)
Under the Federal Food, Drug, and Cosmetic Act (FFDCA, 21 U.S.C. §§301 et seq.), the Food and Drug Administration (FDA) in the Department of Health and Human Services (HHS) has primary responsibility for ensuring the safety and effectiveness of pharmaceuticals, regardless of whether they are controlled substances. See CRS Report R41983, How FDA Approves Drugs and Regulates Their Safety and Effectiveness. Methadone, buprenorphine, and naltrexone are subject to the FFDCA.

Controlled Substances Act (CSA)
Under the Controlled Substances Act (CSA, 21 U.S.C. §§801 et seq.), the Drug Enforcement Administration (DEA) in the Department of Justice (DOJ) has primary responsibility for regulating the use of controlled substances for legitimate medical, scientific, research, and industrial purposes, and for preventing these substances from being diverted for illegal purposes. See CRS Report R45164, Legal Authorities Under the Controlled Substances Act to Combat the Opioid Crisis. Methadone and buprenorphine are controlled under the CSA. Naltrexone, which carries no known risk of abuse, is not controlled under the CSA.

As shown in Table 1, methadone, buprenorphine, and naltrexone are classified differently under the CSA, which assigns various plants, drugs, and chemicals to one of five schedules based on accepted medical use, potential for abuse, and severity of potential psychological or physical dependence. Schedule I contains substances that have no currently accepted medical use and are not available by prescription (such as heroin). Schedules II, III, IV, and V include substances that have recognized medical uses and are progressively less dangerous and addictive.

Table 1. FDA-Approved Medications for Opioid MAT

<table>
<thead>
<tr>
<th>Medication</th>
<th>Class</th>
<th>CSA Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>Full Opioid Agonist</td>
<td>II</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Partial Opioid Agonist</td>
<td>III</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>Opioid Antagonist</td>
<td>none</td>
</tr>
</tbody>
</table>

Source: Prepared by the Congressional Research Service based on information publicly available from FDA and DEA.
Opioid Treatment Programs (OTPs)
Under the CSA, responsibility for regulating OTPs falls to both DEA in DOJ and the Substance Abuse and Mental Health Services Administration (SAMHSA) in HHS. OTPs must obtain

- accreditation from a SAMHSA-approved accreditor,
- certification from SAMHSA, and
- registration from DEA.

Programs meeting all requirements may “administer or dispense directly (but not prescribe)” any drug approved by FDA for treatment of opioid addiction. They may also administer a drug being studied for treatment of opioid addiction, as authorized by FDA under an investigational new drug application.

With few exceptions, the use of methadone to treat opioid addiction is limited to OTPs, which may also offer other forms of MAT, including buprenorphine for detoxification or maintenance and naltrexone for relapse prevention.

OTPs generally administer methadone on a daily basis with staff observing as a patient takes an oral dose of liquid methadone; however, a stable patient may receive a few take-home doses (e.g., for a weekend).

According to SAMHSA’s National Survey of Substance Abuse Treatment Services, most U.S. substance abuse treatment facilities (90%) do not have OTPs. As of the beginning of 2018, 1,317 of the 13,585 U.S. facilities had OTPs, with 382,867 clients in treatment with methadone at these centers.

**OTP Accreditation**
Accreditation is based on a peer review process in which SAMHSA-approved accrediting organizations evaluate OTPs by making site visits and reviewing policies, procedures, and practices. Examples of accrediting organizations include the Joint Commission and the Commission on Accreditation of Rehabilitation Facilities.

**OTP Certification**
Certification is based on SAMHSA’s determination that an accredited program is qualified to carry out treatment conforming to standards in federal regulation. SAMHSA uses the results of the accreditation process as well as other information to determine whether a program is qualified. SAMHSA promulgates guidelines to help accrediting organizations and OTPs conform to treatment standards.

**OTP Registration**
Registration with DEA as an OTP is separate from—and in addition to—the DEA registration required of any “person” (including a hospital, pharmacy, or doctor, among others) who handles controlled substances. OTPs must also comply with relevant DEA regulations addressing records maintenance, security controls, and other matters.

DATA-Waived Providers (DWPs)
Under the Drug Addiction Treatment Act of 2000 (DATA 2000, P.L. 106-310), a physician may obtain a waiver to treat opioid addiction with buprenorphine (but not methadone) outside an OTP. DATA 2000 waives the requirement for separate DEA registration as an OTP if both the practitioner and the medication meet specified conditions. As of June 1, 2019, the number of DATA-waived providers exceeded 67,000; the number is updated daily on SAMHSA’s website.

**Practitioner Requirements**
To qualify for a waiver, a practitioner must notify the HHS Secretary of the intent to use opioid replacement therapy and certify that he or she is a qualifying practitioner (licensed under state law with expertise as evidenced by certification, training, or experience); have the capacity to refer patients for counseling and other services; and comply with a limit on the number of patients. The patient limit is 30 during the first year, may increase to 100 after one year or immediately if the practitioner holds additional credentialing (42 C.F.R. §8.2) or operates in a qualified practice setting (42 C.F.R. §8.615), and may increase to 275 under conditions specified in regulation (42 C.F.R. §8.610 et seq. per the SUPPORT Act).

The SUPPORT Act (P.L. 115-271) made permanent an authority for qualifying nurse practitioners and physician assistants to obtain DATA waivers and expanded the definition of “qualifying other practitioners” to include clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives.

**Medication Requirements**
DATA-waived providers (DWPs) may administer, dispense, or prescribe opioid replacement therapy using a medication that is a narcotic drug in schedule III–V, that is FDA-approved for use in detoxification or maintenance treatment, and that has not been the subject of an adverse determination (as defined in statute). Buprenorphine is currently the only medication to meet the conditions for a DATA waiver.

Table 2 summarizes who can administer, dispense, or (in some cases) prescribe different types of MAT.

<table>
<thead>
<tr>
<th>Medication</th>
<th>OTPs</th>
<th>DWPs</th>
<th>Other Prescribers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Source: CRS analysis of 21 U.S.C. §§801 et seq. and SAMHSA data.

**Johnathan H. Duff**, Analyst in Health Policy
Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.